Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

In GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). The current analysis describes minimal residual disease (MRD) kinetics and any po...

Descripción completa

Detalles Bibliográficos
Autores principales: Munir, Talha, Moreno, Carol, Owen, Carolyn, Follows, George, Benjamini, Ohad, Janssens, Ann, Levin, Mark-David, Osterborg, Anders, Robak, Tadeusz, Simkovic, Martin, Stevens, Don, Voloshin, Sergey, Vorobyev, Vladimir, Yagci, Munci, Ysebaert, Loic, Qi, Keqin, Qi, Qianya, Parisi, Lori, Srinivasan, Srimathi, Schuier, Natasha, Baeten, Kurt, Howes, Angela, Caces, Donne Bennett, Niemann, Carsten U., Kater, Arnon P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351955/
https://www.ncbi.nlm.nih.gov/pubmed/37279408
http://dx.doi.org/10.1200/JCO.22.02283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351955/
https://www.ncbi.nlm.nih.gov/pubmed/37279408
http://dx.doi.org/10.1200/JCO.22.02283

Ejemplares similares